Silexion Therapeutics's total assets for Q3 2025 were $11.61M, an increase of 100.35% from the previous quarter. SLXN total liabilities were $4.64M for the fiscal quarter, a -18.32% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.